4.7 Review

Old and New Challenges in Uveitis Associated with Behcet's Disease

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/jcm10112318

Keywords

uveitis; retinal vasculitis; Behcet's disease; anti-TNF alpha agent; tocilizumab; biologics

Ask authors/readers for more resources

Behcet's disease is a systemic vasculitis disease primarily affecting young individuals, characterized by ocular involvement, venous and arterial occlusion, and potential rapid and severe vision loss. Early therapeutic intervention is crucial, but diagnosis remains a challenge.
Behcet's disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage. The aim of this review is to provide current data on how innovations in clinical evaluation, investigations and treatments were able to improve the prognosis of uveitis associated with BD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available